It works a different switch than painkillers. NSAIDs block the COX enzymes, which also happen to protect the stomach lining and tune kidney blood flow, which is why daily use slowly chews on both. Boswellia's active molecule, AKBA, blocks a separate enzyme, 5-LOX, that runs the body's other main inflammation route ¹. Two switches, one body. That is why the harm bill NSAIDs run up never comes due, and why the two can be combined without much overlap.

The strong case is the knee. Six placebo-controlled trials at standardized doses show meaningful pain reduction within weeks, held at three months. The anchor trial ran 250 mg a day of a 30%-AKBA extract; scores improved by day 7 and a cartilage-degrading blood marker dropped too, a hint it slows the damage and not just the pain ². A pooled meta-analysis puts the effect around a 17-point drop on a 100-point pain scale ³ — noticeably better, not gone. One head-to-head found the pain relief lasted a full month after people stopped ⁴.

Smaller but consistent signals sit outside the knee: remission in mild ulcerative colitis ⁵, and breathing gains in one asthma trial ⁶. Treat those as adjuncts a specialist adds on top of the real drug.

For a chronic knee, this is the whole routine.

The arc is slow and quiet. By two weeks the morning stiffness shortens and the first ten steps out of bed stop being a negotiation. By six to eight weeks the ache on stairs and uneven ground recedes into something quieter, and the walk to the corner shop stops needing a decision. By three months the rescue ibuprofen that used to pile up after yardwork drops out of the rhythm, and with it the slow stomach and heart risk those doses carry. Most people describe it as feeling more like themselves, not as a knee that feels better.